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Physical and mental health comorbidity is
common in people with multiple sclerosis:
nationally representative cross-sectional
population database analysis
Robert J Simpson1*, Gary McLean1, Bruce Guthrie2, Frances Mair1 and Stewart W Mercer1
Abstract
Background: Comorbidity in Multiple Sclerosis (MS) is associated with worse health and higher mortality.
This study aims to describe clinician recorded comorbidities in people with MS.
Methods: 39 comorbidities in 3826 people with MS aged ≥25 years were compared against 1,268,859 controls.
Results were analysed by age, gender, and socioeconomic status, with unadjusted and adjusted Odds Ratios (ORs)
calculated using logistic regression.
Results: People with MS were more likely to have one (OR 2.44; 95% CI 2.26-2.64), two (OR 1.49; 95% CI 1.38-1.62),
three (OR 1.86; 95% CI 1.69-2.04), four or more (OR 1.61; 95% CI 1.47-1.77) non-MS chronic conditions than controls,
and greater mental health comorbidity (OR 2.94; 95% CI 2.75-3.14), which increased as the number of physical
comorbidities rose. Cardiovascular conditions, including atrial fibrillation (OR 0.49; 95% CI 0.36-0.67), chronic kidney
disease (OR 0.51; 95% CI 0.40-0.65), heart failure (OR 0.62; 95% CI 0.45-0.85), coronary heart disease (OR 0.64; 95% CI
0.52-0.71), and hypertension (OR 0.65; 95% CI 0.59-0.72) were significantly less common in people with MS.
Conclusion: People with MS have excess multiple chronic conditions, with associated increased mental health
comorbidity. The low recorded cardiovascular comorbidity warrants further investigation.
Background
Multiple Sclerosis (MS) is a chronic, debilitating disease
that can cause widespread damage to the nervous system,
with potentially devastating physical, psychological, voca-
tional, and social consequences [1] and because of its
progressively disabling nature significant health care and
social costs accumulate [2]. Scotland has the highest
prevalence of MS worldwide, with a number of potential
aetiological factors implicated, including genetics, infec-
tion, low sun exposure, and diet [3-5].
Comorbidity is common in MS, and particular patterns
of comorbid disease predominate. Given the high level of
medical contact and input that people with MS can re-
quire, surveillance bias may be a factor in these findings,
although clear-cut research data appears lacking in this
regard. Comorbidity can be defined as any additional con-
dition (over and above MS) requiring treatment, or which
alters organ function [6]. Common comorbid conditions
include anxiety, depression, and bipolar disorder, as well
as a variety of physical conditions, including autoimmune
disorders, gastrointestinal dysfunction, arthritis, visual
impairment, and possibly cardiovascular (CV) diseases
[7-12]. However, studies have ranged in terms of sampling,
sample size, and the number and type of comorbidities
recorded.
In Taiwan, using a modified version of the Elixhauser
Comorbidity Index, Kang et al. [11] reported on findings
from a national health insurance research database on 30
comorbidities amongst a group of 898 patients with MS
compared against 4490 randomly matched controls. They
found that people with MS had higher rates of both
psychiatric (depression, dementia, psychoses) and various
medical (neurological, pulmonary, endocrine, autoimmune,
renal, gastrointestinal, infectious, haematological, and
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oncological) comorbidities. In Canada, Warren et al. [10]
used the Canadian Community Health Survey to extract
comorbidity data for people with MS, and examined the
prevalence of 21 self-reported comorbdities in 335 indi-
viduals including medical and psychiatric complaints.
They found that the mean number of comorbidities
reported was 1.6, and that 10% of respondents reported 8
or more [10]. In the United States (US), Marrie et al. [9]
assessed the prevalence of 33 self-reported comorbidities
in 8983 people with MS aged 16–60 which comprised
7-10% of the US MS population (although was not
nationally representative). They reported that multiple
comorbidity was present in 77.1% (6907/8983) of partici-
pants, with 30.4% (n = 2907) having one comorbidity,
25.6% (n = 1766) having two, and 44.1% (n = 3044) having
three or more. Marrie et al. [9] found that comorbidity was
more likely amongst men, the older aged, those of lower
socio-economic status, and those of African American
ethnicity. The comorbidities included in the Marrie et al.
[9] study were reported as being selected on the basis of
their being either frequently reported in the general popu-
lation, or frequently reported amongst those with MS. The
respondents to the survey were mostly female (75.8%) and
Caucasian (94.3%), with the study authors noting that non-
responders were significantly more likely to be younger, of
lower socio-economic status, non-Caucasian ethnicity, and
more disabled.
The aim of this study is to describe a wide range of
clinician recorded physical and mental comorbidities
(n = 39) in people with MS, compared to controls, in a
large and nationally representative primary care popula-
tion in Scotland.
Methods
Analysis used cross-sectional data from a nationally
representative Scottish Primary Care dataset, supplied by
the Primary Care Clinical Informatics Unit, University of
Aberdeen, UK, as part of a programme of research on
multimorbidity [13]. The anonymous use of this data
has prior approval from the United Kingdom National
Health Service National Research Ethics Service [13].
The dataset holds clinical information on 1,751,841 indi-
viduals, registered with 314 general practices across
Scotland, which was extracted in April 2007, and is a
complete copy of all historical data at that point. The pa-
tient data is for approximately one third of the Scottish
population and is nationally representative in terms of
age, gender, and socioeconomic status. In Scotland, all
general practices use electronic records, and have done so
extensively since the late 1990’s for managing their regis-
tered lists, for prescribing, and for the recording of
morbidities using a standard coding system (Read Codes).
MS was defined as the presence ever of a Read Code for
MS using a code-set created by NHS Scotland Information
Services Division [14]. Thirty-nine other chronic condi-
tions were defined, as reported previously [13], including 8
mental health conditions and 31 other physical health con-
ditions. The 40 conditions included (39 others plus MS)
were based on the recording by a clinician of a relevant
Read Code in an individual’s electronic clinical record and/
or on prescription of relevant drugs. The conditions were
derived from a combination of recent systematic review
evidence (11 conditions), diseases included in the UK
General Practice contract Quality and Outcomes Frame-
work (16 conditions), and those specified by NHS Scotland
as important for health service planning (26 conditions)
(see [13] for details). Extracted data included information
on: age, gender, and socioeconomic status (Carstair’s score
based on post codes) [15]. Due to the low numbers of
people with MS under the age of 25 years, the analysis was
restricted to all people aged ≥25 years. Analysis is therefore
based on data for 1,268,859 individuals.
Statistical analysis
Analysis was descriptive and compared comorbidity in
people with and without MS. T tests were used to exam-
ine differences in mean number of morbidities, and chi-
squared tests to examine differences in the percentage of
people with comorbidity across variables. Binary logistic
regression examined associations between comorbidities
in people with MS versus controls. Odds ratios (ORs)
adjusted for age, sex and deprivation, with 95% confidence
intervals, are reported for people with MS versus the gen-
eral population. All analysis was undertaken using
SPSS v19.
Results
Of the 1,268,859 individuals in the analysis, 3826 (0.3%;
95% CI 0.29-0.31) had a diagnosis of MS, of which 2767
(72.3%) were female. People with MS were on average
slightly older than the unaffected population (mean age
53.4 years versus 51.2 years for controls; p < 0.001).
People with MS were also marginally less socioeconomi-
cally deprived, as measured by the Carstair’s Score
(mean value −0.64 versus −0.22; p < 0.001) (see Table 1).
After adjusting for age, sex, and deprivation, those with
MS were significantly more likely to have greater than
one other chronic condition (OR 2.44; 95% CI 2.26-2.64)
(see Table 2).
There was no difference found between women and
men with MS, with respect to: age, deprivation, or total
physical comorbidity count (results not shown). Female
patients were significantly more likely to have a mental
comorbidity than males (OR 1.26; 95% CI 1.09-1.46),
after adjusting for age and deprivation (see Table 3).
People with MS had higher levels of chronic conditions
after controlling for age, sex and deprivation (OR 2.44; 95%
CI 2.26-2.64) and especially mental health comorbidity
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(OR 2.94; 95% CI 2.75-3.14). People with MS were more
likely to have one (OR 2.44; 95% CI 2.26-2.64), two (OR
1.49; 95% CI 1.38-1.62), three (OR 1.86; 95% CI 1.69-2.04),
or four or more (OR 1.61; 95% CI 1.47-1.77) non-MS
chronic conditions than controls (see Table 2), and as the
number of physical morbidities rose, both men and women
with MS were consistently more likely to have a mental
health comorbidity than the controls (see Figure 1).
Comorbidity of mental conditions in people with MS
People with MS had a higher prevalence for four of the
eight mental conditions examined after adjustment for
age, sex and socioeconomic status (Figure 2); being high-
est for depression (OR 3.33; 95% CI 3.10-3.57), followed
by anxiety (OR 3.18; 95% CI 2.89-3.50), and problematic
drug use (OR 2.03; 95% CI 1.77-2.32) (a mixed cat-
egory that includes a range of problems associated with
prescription and non-prescription drug use). A diagnosis
of an eating disorder was more prevalent (OR 1.72; 95%
CI 1.20-2.45), but the numbers within the eating disorder
group were very small (n = 31). There was no statistically
significant difference in prevalence of schizophrenia/
bipolar disorder (OR 1.07; 95% CI 0.78-1.47) or learning
disability (OR 0.66; 95% CI 0.33-1.32), whilst dementia
(OR 0.66; 95% CI 0.47-0.94), and alcohol misuse (OR
0.68; 95% CI 0.54-0.87) were significantly less common
amongst people with MS.
Comorbidity of physical conditions in people with MS
Figure 3 shows that of the thirty physical conditions
assessed, the prevalence was higher in the MS group
than controls for ten conditions, lower for eleven, and
no different for nine conditions. Prevalence was highest
in people with MS (versus controls) for constipation
(OR 6.61; 95% CI 6.00-7.27), visual impairment (OR
4.06; 95% CI 3.33-4.96), chronic pain (OR 3.43; 95% CI
3.18-3.70), migraine (OR 2.38; 95% CI 1.91-2.97), and epi-
lepsy (OR 2.20; 95% CI 1.74-2.77). In contrast, people with
MS had a significantly lower prevalence for the majority
of cardiovascular (CV) conditions, including atrial fibrilla-
tion (OR 0.49; 95% CI 0.36-0.67), chronic kidney disease
(OR 0.51; 95% CI 0.40-0.65), heart failure (OR 0.62; 95%
CI 0.45-0.85), coronary heart disease (OR 0.64; 95% CI
0.52-0.71), and hypertension (OR 0.65; 95% CI 0.59-0.72).
Discussion
This study presents findings on the prevalence of
comorbidity in patients with MS, based on analysis of a
large, geographically and nationally representative Pri-
mary Care clinical dataset. Consequently it strengthens
the existing evidence already suggesting that comorbidity
is common in patients with MS; specifically by reporting
on a wider range of comorbidites than any previous
comparable study in the field.
Comorbidity of other chronic conditions appears to be
common in people with MS [9-11]. Prior research high-
lights targeted management of such conditions in people
with MS as being important [9,10,16]. However, there is
Table 1 General characteristics: MS vs non-MS
MS
(>25yrs)
Non-MS
(>25yrs)
Significance p
n (%) n (%)
Total 3,826 1,268,859
Gender (% female) 2,767 (72.3) 647,836 (51.1) p<0.0001
Mean age (SD) 53.4 (12.8) 51.2 (16.6) p<0.0001
Mean deprivation (SD) -0.64 (3.0) -0.2 (3.3) p<0.0001
Age group
25-44 1018 (26.6) 507371 (40.0) p<0.0001
45-64 2083 (54.4) 471044 (37.1) p<0.0001
65-84 685 (17.9) 253915 (20.0) p=0.0006
85+ 40 (1.0) 36529 (2.9) p<0.0001
Carstair’s deprivation
Quintile (min-max score)
Q1 least deprived 813 (21.2) 243545 (19.2) p=0.0006
Q2 889 (23.2) 274878 (21.7) p=0.009
Q3 913 (23.9) 289037 (22.8) p=0.06
Q4 687 (18.0) 241207 (19.0) p=0.049
Q5 most deprived 524 (13.7) 220192 (17.4) p<0.0001
Table 2 Comorbidity prevalence and type in people with and without MS
MS n (%) Non-MS n (%) OR* (95% CI)
Significance p
No comorbidity 1,027 (26.8) 597,363 (47.1) 0.20 (0.18-0.22) p<0.001
One 2,799 (73.2) 671,496 (52.9) 2.44 (2.26-2.64) p<0.0001
Two 714 (18.7) 159,293 (12.6) 1.49 (1.38-1.62) p<0.0001
Three 546 (14.3) 97,368 (7.7) 1.86 (1.69-2.04) p<0.0001
Four or more 669 (17.5) 136,847 (10.8) 1.61 (1.47-1.77) p<0.0001
Any physical comorbidity 2,475 (64.7) 600,669 (47.3) 2.05 (1.90-2.21) p<0.0001
Any mental health comorbidity 1,541 (40.3) 227,361 (17.9) 2.94 (2.75-3.14) p<0.0001
*Odds Ratios adjusted for Age, Sex and Deprivation Scores.
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an increasing body of evidence suggesting that, around
the world, health-care systems, medical education and
medical research paradigms are generally not well equip-
ped to address the rising prevalence of people living with
multiple conditions. Services have been described as frag-
mented, and largely orientated towards single-disease
models of care, which can be inefficient, unsafe, and can
fail to recognise the compound effects of conditions which
serves to add to disease burden [13]. Comorbidity in gen-
eral is associated with reduced functional status, lower
quality of life, increased usage of health-care services, and
higher mortality rates [13].
People with MS are already known to have reduced
health-related quality of life (HRQOL) [17]; and this
may be considerably worse in those with comorbidities,
with the potential for such conditions to act synergistically
to reduce HRQOL [18], which is in keeping with findings
in other chronic conditions [10,19]. Comorbidity has pre-
viously been demonstrated to delay the time to primary
diagnosis in people with MS, possibly by obscuring symp-
toms that might otherwise be attributed to a new diagno-
sis [20]. Furthermore, the presence of comorbidity at the
time of initial diagnosis has been shown to be associated
with increased disability levels [20].
In this study, mental health co-morbidities in people
with MS were almost three times as common, compared
to the general population, with anxiety and depression
being particularly prevalent. This matters because both
have been associated with increased suicidal ideation in
people with MS, whilst depression is noted to be a key
predictor of quality of life, morbidity, and mortality [21].
Anxiety in people with MS, though poorly understood,
often increases sharply after initial diagnosis, and is par-
ticularly common in female patients [21]. It is known to
be associated with greater social dysfunction, increased
reporting of physical complaints, excess alcohol usage, and
is noted in the literature as being both under-recognised
Table 3 Gender differences in co-morbidity in people
with MS
Physical conditions
(Including MS)
MS Population characteristics
Female Male OR* (95% CI)
n (%) n (%) Significance p
2+ 1801(64.6) 678 (63.7) 1.07 (0.91 1.25) p=0.37
3+ 1021 (36.6) 401 (37.7) 0.98 (0.84 1.14) p=0.55
Mental conditions
At least 1 1156 (41.8) 385 (36.4) 1.26 (1.09 1.46) p=0.02
2+ 112 (4.0) 55 (5.2) 1.02 (0.91 1.13) p=0.69
*Odds Ratios adjusted for Age and Deprivation Scores.
Figure 1 Association between number of physical conditions and presence of any mental health condition.
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Figure 2 Odds ratios for individual mental conditions: people with MS (n = 3826) vs controls (n = 1,268,859). *Odds Ratios adjusted for
Age, Sex and Deprivation Scores. Note on abbreviations [13]: Depression = Read code recorded in last 12 months OR ≥4 anti-depressant
prescriptions (excluding low dose tricyclics) in last 12 months; Anxiety = Anxiety & other neurotic, stress related & somatoform disorders, Read
code in last 12 months OR≥ 4 anxiolytic/hypnotic prescriptions in last 12 months. OR ≥4 10/25 mg amitriptyline in last 12 months & do not meet
the criteria for ‘Pain.’; Drugs Misuse = Other psychoactive substance misuse; Eating Disorder = Anorexia or Bulimia; Bipolar/Schizo = Schizophrenia
(and related non-organic psychosis) or bipolar disorder, Read code ever recorded/recorded in last 12 months (code dependent) OR Lithium
prescribed in last 168 days.
Figure 3 Odds ratios for individual physical conditions: people with MS (n = 3826) vs controls (n = 1,268,859). *Odds Ratios adjusted for
Age, Sex and Deprivation Scores. Note on abbreviations [13]: Constipation = ≥4 laxative prescriptions in last year; Pain = ≥4 prescription only
medicine analgesic prescriptions in last 12 months OR ≥4 specified anti-epileptics in the absence of an epilepsy Read code in last 12 months;
Migraine =≥4 prescription only medicine anti-migraine prescriptions in last year; Epilepsy = Read code ever recorded AND antiepileptic
prescription in last 12 months; IBS = Read code ever recorded OR≥ 4 prescription only medicine antispasmodic prescription in last 12 months;
Parkinson’s Disease = Parkinson’s Disease and Parkinsonism; Psoriasis or Eczema = Read code ever recorded AND≥ 4 related prescriptions in last
12 months (excluding simple emollients) Dyspepsia =≥ 4 prescriptions in last 12 months excluding antacids AND NOT (≥4 NSAIDS OR ≥4
aspirin/clopidogrel) IBD = inflammatory bowel disease; PVD = Peripheral vascular disease; Stroke = Stroke and Transient ischaemic attack;
COPD = Chronic obstructive pulmonary disease; CKD = Chronic kidney disease; Inflammatory Arthritis = Rheumatoid arthritis, other inflammatory
polyarthropathies & systematic connective tissue disorders; Asthma = Read code ever recorded AND any prescription in last 12 months.
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and under-treated [21]. Our findings resonate with the
published literature in this sphere, although others have
reported even higher levels of depression, but less anxiety
[7,22,23]. Speculative links have been drawn between the
neuroinflammatory process and the development of de-
pression in people with MS, but the aetiology for depres-
sion is complex, likely to be multifactorial, and remains
unclear [24], although it is worth noting that depression is
a very frequent comorbidity of all physical disease [13].
Recent research has drawn attention to an increased
prevalence of bipolar disorder in people with MS [25].
This association was not suggested by the data in our
study, which generated a composite (and hence, limited).
Prevalance for bipolar disorder (combining schizophrenia,
other psychoses, and severe bipolar disorder). However, it
is important to note that there is a growing international
literature expounding the hypothesis that bipolar spec-
trum disorders are in fact frequently misdiagnosed as
major depressive disorder; most pertinently in the Primary
Care setting [26,27]. This is an important point, given that
treatment with antidepressants may in fact be harmful in
this population, and there are notably high rates of suicide
associated with a diagnosis of bipolar disorder.
Recognition and treatment of mental comorbidity in
people with MS is important, for the reasons outlined
above. Screening in this group, as others have suggested
[21,28], may be worthy of consideration. However, the
use of such measures in other chronic diseases has been
controversial, so any such approach to screening would
need careful evaluation [29].
Physical comorbidities were present in nearly two
thirds of those with MS, being twice as likely to be
found in those without MS, after controlling for age, sex
and deprivation. There were notably high levels of ner-
vous system co-morbidities in our study, with chronic
pain, migraine and epilepsy all being more than twice as
likely to be diagnosed in people with MS, which is in
line with the literature. For example, Koch et al. [30] de-
scribed a prevalence of seizures between 0.5% and 8.3%
in people with MS (compared with 1.9% with a diagnosis
of active epilepsy in our study (Read Code recorded ever
plus anti-epileptic treatment in the previous 12 months));
whilst Kratz et al. [31] described prevalence rates for a self-
report survey of chronic pain at up to 50% (as compared to
27.5% of people prescribed 4 or more prescription-only
analgesics per year or a pain modifying drug in our study).
Chronic pain can impact directly onto levels of psycho-
logical stress, with increased utilisation of health care
services, diminished quality of life, and more disability [31].
Similarly, a high prevalence of migraine in people with MS
has been reported elsewhere [10,32], however, Pakpoor
et al. [33] have pointed out in a recent meta-analysis that
the relationship between migraine and MS is complicated,
with cortical demyelination believed to enhance cortical
spreading depression. Visual impairment was over 4 times
more likely to be reported amongst people with MS, and
this is likely to reflect optic neuritis and its ramifications,
which have important implications for both quality of life
and lasting visual function. Our high prevalence findings
reflect similar results reported from the US [12].
Gastrointestinal diagnoses, such as constipation, dys-
pepsia, and irritable bowel syndrome (IBS) were more
commonly observed in the MS population. Neurogenic
bowel dysfunction symptoms are common in people with
MS, although whether this represents a separate disease
entity is unclear at present [34]. Marrie et al. [9] reported
increased prevalence of IBS, in a comparable MS patient
population (n = 8983) in the US, at even higher levels than
those found in this current sample, but these numbers
were based on patient self-report [9].
Of particular note, our study demonstrated a lower
prevalence overall for recorded cardiovascular conditions
amongst those with MS, when compared to the general
population. Cardiovascular pathologies have been repor-
ted to lead to greater disability levels in those with MS
[35]; and in their own right (cerebrovascular disease,
hypertension, hypercholesterolaemia, and diabetes), these
conditions are all known to independently be related to
both loss of brain mass and function [35]. Research to
date has demonstrated conflicting evidence regarding
cardiovascular disease amongst people with MS, with
a recent systematic review reporting a likely overall in-
creased risk for cardiovascular disease amongst people with
MS [36]. The same study also reported that identifying
clear cut traditional risk factors (obesity, hypertension, dys-
lipidaemia, diabetes) that might explain this relationship
remains problematic, and suggests that further research in
this area is required [36].
Both neurological, and certain gastrointestinal condi-
tions, stand out as over-represented amongst the physical
comorbidities. Whether this represents a consequence of
MS, its treatments, or of independent comorbidities arising
de novo remains unclear. Cardiovascular conditions are re-
markably under-represented in this sample, which is par-
ticularly notable, given the high rates of cardiovascular
disease in Scotland. These findings are comparable to those
of Smith et al. [37], who analysed the same dataset and
discovered surprisingly low levels of recorded cardiovascu-
lar disease amongst patients with Schizophrenia. In both
cases, it seems likely that this is at least partly due to
under-diagnosis in Primary Care. In the case of people with
MS, clinicians and researchers alike should adopt extra
vigilance for the potential under-appreciation of cardiovas-
cular dysfunction, given the likely benefits of intervention.
Strengths and limitations
This study is important given the size and representa-
tiveness of the sample in the country with the highest
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prevalence of MS in the world. It is notable that the preva-
lence for MS in our sample is comparable (although
somewhat higher) to that reported by MacKenzie et al.
[38], who reviewed data from the General Practice
Research Database from between 1990–2010 (which,
although a larger sample in terms of total numbers
included, contains a smaller, non-nationally representative
cohort of Scottish Primary Care patients – 9.9% of the
Scottish population [39]). To our knowledge our data
represents the largest clinician recorded dataset for MS
comorbidities in the research literature, and reports on
the largest number of comorbidities.
Due to the nature of the data available for our analysis,
it was not possible to distinguish whether comorbidities
were present prior to the diagnosis of MS being applied,
or occurred thereafter. The dataset was not designed
specifically to study comorbidity in people in MS, and
like all routine data analyses it is therefore limited by the
quality of the data recording by clinicians, although the
use of electronic medical records has been routine in
primary care in Scotland since the late 1990s and data
recording for common conditions is generally good
(however, it is important to note that the positive pre-
dictive value for the accuracy of Read Codes in record-
ing diagnoses of MS is far from perfect, with Khan et al.
[40] demonstrating rates of around 60% in their system-
atic review on the topic). Additionally, prescribing data
was used to define some conditions in our database, but
many drugs have off licence or secondary indications in
those with MS (for example to treat spasticity) which
may lead to some subtle misclassification. The conditions
included in the dataset represent a diverse mixture of
morbidities taken from front line clinical practice and
prescribing data, and for the purposes of studying
MS, it is worth noting that several of these morbidities
could potentially be considered as ‘concordant conditions’
(although, to our knowledge, this concept is not well
explicated in the MS literature), or even as symptoms of
the disease itself. It is also worth pointing out that this
descriptive cross-sectional analysis is necesarilly limited by
its purposes and the data collected, in that there is no data
on disease duration, course, or severity, which precludes
both weighting and further analysis by incorporating a
specific comorbidity index, beyond that of simply referring
to comorbidity count.
Conclusions
Comorbidity is very common in people with MS, and sig-
nificantly more common than in the general population,
with certain conditions much more likely to be present.
Mental health comorbidities, and in particular anxiety and
depression, are widespread amongst people with MS. Like
the general population, mental health conditions are more
likely to be present in people with MS as the number of
physical conditions increases, but this relationship is
stronger in people with MS. Intriguingly, cardiovascular
disease is less likely to be present, although whether this is
due to reduced case finding and diagnosis in people with
MS or a true difference in prevalence is uncertain. The
relationship with cardiovascular disease requires further
research, as does the consequences of high rates of mental
health comorbidity on physical function and prognosis.
Based on experience of physical-mental health comorbid-
ity in conditions like diabetes and coronary heart disease
[41,42], interventions are likely to be complex and go
beyond drug therapies, and it is likely that interventions
tailored to the needs of people with MS will be required.
Meantime, clinicians should be alert to the possibility of
co-existing mental health conditions and actively treat
them if required.
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